Novel Targeted Therapy for EGFR Exon 20–Positive NSCLC
Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.
Watch
Expert Perspectives on a Case of Stage 4 NSCLC
Expert oncologist Zofia Piotrowska, MD, reviews the case of a patient managed with frontline chemotherapy after receiving a diagnosis of stage 4 NSCLC.
Addressing Drug Resistance Due to Mutations in HER2+ Breast Cancer
Ron Bose, MD, PhD, discusses the challenge of drug resistance due to mutations for patients with HER2-positive breast cancer.
Current Options for Treating Non-Melanoma Skin Cancers
Valencia Thomas, MD, MHCM, discusses the current landscape regarding non-melanoma skin cancers.
Changes in the Management of TP53-Mutant AML
Melhem Solh, MD, discusses how the standard of care for patients with myelodysplastic syndrome and acute myeloid leukemia with the tumor protein 53 gene mutation has changed over the past decade.
Haploidentical Transplant for Patients Without HLA-Matched Donors
Anne Wooford, MD, provides background on her presentation around allogeneic stem cell transplant for the 2022 Transplantation & Cellular Therapy Meetings.
Managing Adverse Events with Superior Combination Therapies in RCC
Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.
DUO-E Trial Focuses on Treating High-Risk Endometrial Cancer
Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.
Future of Targeting EGFR Exon 20 Insertion Mutations in NSCLC
Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing.
Experience With Amivantamab and Mobocertinib in EGFR Exon 20 Insertion–Positive NSCLC
Expert Joel Neal, MD, PhD, shares personal experience and highlights adverse event management strategies with amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC.
Factors Correlating With Survival in Polycythemia Vera
Carole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.
EGFR Exon 20 Insertion–Positive NSCLC: CHRYSALIS and EXCLAIM Trial Outcomes
The trial results of CHRYSALIS and EXCLAIM, which investigated amivantamab and mobocertinib, respectively, as second-line therapy for EGFR exon 20 insertion–positive NSCLC.
Novel Second-Line Therapy for EGFR Exon 20 Insertion-Positive NSCLC
A comprehensive discussion on novel second-line agents amivantamab and mobocertinib, approved for EGFR exon 20 insertion–positive non–small cell lung cancer.
EGFR Exon 20 Insertion–Positive NSCLC: Overview of Treatment Options
Expert perspective on the treatment armamentarium for EGFR exon 20 in non–small cell lung cancer.
Optimizing Molecular Testing and Treatment Strategies in NSCLC
Expert Joel Neal, MD, PhD, shares his perspectives on the frontline management of NSCLC and optimal strategies for molecular profiling in this setting.
A Case of EGFR Exon 20 Insertion–Positive NSCLC
A case of a 64-year-old man with non–small cell lung cancer, who tested positive for an EGFR exon 20 insertion mutation after progression on frontline therapy.
Choosing Second-Line Therapy for HER2+ Gastric Cancer
Bassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.
The Future of Myelofibrosis Treatment
Dr John Mascarenhas looks to the future of myelofibrosis treatment and shares some ongoing clinical trials and potential treatments that excite him.
Review of the PERSIST-1 and PERSIST-2 Trials
John Mascarenhas, MD, describes his personal experience with using pacritinib to treat patients with myelofibrosis and reviews the study design and outcomes for both the PERSIST-1 and PERSIST-2 trials.
Mechanism of Action of Pacritinib
Dr John Mascarenhas reviews the mechanism of action of pacritinib, a selective JAK2 inhibitor.
Considerations in Choosing a Treatment for Myelofibrosis
An expert describes the factors he considers when choosing a treatment for a patient with myelofibrosis, and how he judges treatment response.
Clinical Phenotypes in Patients with Myelofibrosis
Dr John Mascarenhas explains the differences between myelofibrosis phenotypes and why it affects treatment regimen choices.
The Role of ASCT After CAR T-Cell Therapy
Robert J. Soiffer, MD, discusses how the role of transplantation is evolving with the availability of chimeric antigen receptor T-cell agents.
Case Presentation: A 76-Year-Old Woman with Myelofibrosis
John Mascarenhas, MD, presents the case of a 76-year-old woman with myelofibrosis and provides his initial impressions.
Mechanism of Action of DKN-01 in Gastroesophageal Adenocarcinoma
Samuel J. Klempner, MD, discusses the mechanism of action of the investigational agent DKN-01 in patients with gastroesophageal adenocarcinoma.
Remaining Unmet Needs and Future Directions in MF
Srdan Verstovsek, MD, PhD, wraps up by discussing remaining unmet needs and hopes for future treatment options for patients with MF.
Considerations for Patient Follow-Up and Management
A commentary on considerations for long-term follow-up and management of myelofibrosis.
Risk of AML and Potential Use of Bone Marrow Transplant in Patients with MF
Srdan Verstovsek, MD, PhD, discusses the risk of transformation to acute myeloid leukemia (AML) and the potential use of bone marrow transplant in patients with MF.
Benefits of Clinical Trial Enrollment for Patients with MF
A discussion of the benefits of clinical trial enrollment for MF.
JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF
Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.
